European Organisation for Research and Treatment of Cancer - EORTC
422
20
43
224
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.6%
87 terminated/withdrawn out of 422 trials
72.0%
-14.5% vs industry average
40%
168 trials in Phase 3/4
10%
23 of 224 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (422)
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Role: collaborator
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
Role: lead
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Role: lead
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Role: collaborator
Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
Role: collaborator
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Role: lead
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Role: lead
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Role: collaborator
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Role: collaborator
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Role: collaborator
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Role: collaborator
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Role: lead
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
Role: lead
FLT3-ITD Targeted Therapy in Fit AML Patients
Role: lead
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Role: lead
Surgery for Recurrent Glioblastoma
Role: collaborator
Management of Low-risk (Grade I and II) DCIS
Role: collaborator
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Role: lead
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
Role: lead
A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
Role: lead